Eliana Clark - Mar 1, 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Technical Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Mar 1, 2024
Transactions value $
-$19,959
Form type
4
Date filed
3/5/2024, 04:10 PM
Previous filing
Jan 5, 2024
Next filing
Jul 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +31.2K +76.46% $0.00 72.1K Mar 1, 2024 Direct F1
transaction NTLA Common Stock Sale -$20K -605 -0.84% $32.99 71.5K Mar 4, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +45.1K $0.00 45.1K Mar 1, 2024 Common Stock 45.1K $32.66 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2024, and does not represent a volitional trade by the Reporting Person.
F3 This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.